Article Data

  • Views 828
  • Dowloads 146

Original Research

Open Access

Long non-coding RNA ROR accelerates the progression of breast cancer via promoting stemness in MCF-10A cells

  • S. Wang1,2,3,4
  • W.J. Chen1,2,3
  • Z.M. Song1,2,3
  • Q. Li1,2,3
  • X. Shen1,2,3
  • Y.D. Wu1,2,3
  • L. Zhu1,2,3
  • Q.X. Ma2
  • D.M. Xing1,2,5,*,

1Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao

2Cancer Institute, Qingdao University, Qingdao

3Qingdao Cancer Institute, Qingdao

4Department of Oncology, Weifang Traditional Chinese Medicine Hospital, Weifang

5School of Life Sciences, Tsinghua University, Beijing (China)

DOI: 10.31083/j.ejgo.2020.01.5289 Vol.41,Issue 1,February 2020 pp.106-109

Published: 15 February 2020

*Corresponding Author(s): D.M. Xing E-mail:


Long non-coding RNA (lncRNA), regulator of reprogramming (ROR) is an intergenic lncRNA previously shown to contribute to tumorigenesis in several malignancies. In their previous study, the present authors found that ROR was highly associated with gastric cancer progression, however, the role of ROR in breast cancer (BC) was still unclear. Here, the authors investigated the role and mechanism of ROR in BC. They found that the expression of ROR was increased in the MCF-7 cells and MDA-MB-231 cells compared with the control MCF-10A. The exogenous expression of ROR was increased using plasmid overexpressing ROR in MCF-10A cells, then the biological function of ROR was determined using MTT assay and Transwell assay. The result indicated that overexpression of ROR could significantly increase the capability of cell proliferation and invasion. Furthermore, the molecular markers for BC stem cell (BCSC) were verified, the results showed that enhanced expression of cluster of differentiation 44 (CD44) and aldehyde dehydrogenase 1 (ALDH1) was observed in MCF-10A cells with ROR overexpression. In summary, this study will further expand our understanding of ROR and provide a new target for the treatment of BC.


Long non-coding RNA; ROR; Breast cancer; CD44; ALDH1.

Cite and Share

S. Wang,W.J. Chen,Z.M. Song,Q. Li,X. Shen,Y.D. Wu,L. Zhu,Q.X. Ma,D.M. Xing. Long non-coding RNA ROR accelerates the progression of breast cancer via promoting stemness in MCF-10A cells. European Journal of Gynaecological Oncology. 2020. 41(1);106-109.


[1] Daly C.S., Flemban A., Shafei M., Conway M.E., Qualtrough D., Dean S.J.: “Hypoxia modulates the stem cell population and induces EMT in the MCF-10A breast epithelial cell line”. Oncol. Rep., 2018, 39, 483.

[2] Feng Z.M., Qiu J., Chen X.W., Liao R.X., Liao X.Y., Zhang L.P., et al.: “Essential role of miR-200c in regulating self-renewal of breast cancer stem cells and their counterparts of mammary epithelium”. BMC. Cancer, 2015, 15, 645.

[3] Sulaiman A., Sulaiman B., Khouri .L, McGarry S., Nessim C., Arnaout A., et al.: “Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and ERalpha coinhibition”. FEBS. Lett., 2016, 590, 4606.

[4] Erol A., Acikgoz E., Guven U., Duzagac F., Turkkani A., Colcimen N., et al.: “Ribosome biogenesis mediates antitumor activity of flavopiridol in CD44(+)/CD24(-) breast cancer stem cells”. Oncol. Lett., 2017, 14, 6433.

[5] Li W., Ma H., Zhang J., Zhu L., Wang C., Yang Y.: “Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis”. Sci. Rep., 2017, 7, 13856.

[6] Li Y., Zhang W., Liu P., Xu Y., Tang L., Chen W., et al.: “Long noncoding RNA FENDRR inhibits cell proliferation and is associated with good prognosis in breast cancer”. Onco. Targets. Ther., 2018, 11, 1403.

[7] Zheng R., Lin S., Guan L., Yuan H., Liu K., Liu C., et al.: “Long non-coding RNA XIST inhibited breast cancer cell growth, migration, and invasion via miR-155/CDX1 axis”. Biochem. Biophys. Res. Commun., 2018, 498, 1002.

[8] Tao F., Tian X., Lu M., Zhang Z.: “A novel lncRNA, Lnc-OC1, promotes ovarian cancer cell proliferation and migration by sponging miR-34a and miR-34c”. J. Genet. Genomics, 2018, 45, 137.

[9] Zhang Y., Cheng X., Liang H., Jin Z.: “Long non-coding RNA HOTAIR and STAT3 synergistically regulate the cervical cancer cell migration and invasion”. Chem. Biol. Interact., 2018, 286, 106.

[10] Loewer S., Cabili M.N., Guttman M., Loh Y.H., Thomas K., Park I.H., et al.: “Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells”. Nat. Gent., 2010, 42, 1113.

[11] Eades G., Wolfson B., Zhang Y., Li Q., Yao Y., Zhou Q.: “lincRNARoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6”. Mol. Cancer. Res., 2015, 13, 330.

[12] Wang S., Liu F., Deng J., Cai X., Han J., Liu Q.: “Long Noncoding RNA ROR Regulates Proliferation, Invasion, and Stemness of Gastric Cancer Stem Cell”. Cell. Reprogram., 2016, 18, 319.

[13] Li J., Liu J., Li P., Mao X., Li W., Yang J., et al.: “Loss of LKB1 disrupts breast epithelial cell polarity and promotes breast cancer metastasis and invasion”. J. Exp. Clin. Cancer. Res., 2014, 33, 70.

[14] Zhao Y., Liu Y., Lin L., Huang Q., He W., Zhang S., et al.: “The lncRNA MACC1-AS1 promotes gastric cancer cell metabolic plasticity via AMPK/Lin28 mediated mRNA stability of MACC1”. Mol. Cancer, 2018, 17, 69.

[15] Wang D.Q., Fu P., Yao C., Zhu L.S., Hou T.Y., Chen J.G., et al.: “Long Non-coding RNAs, Novel Culprits, or Bodyguards in Neurodegenerative Diseases”. Mol. Ther. Nucleic. Acids, 2018, 10, 269.

[16] Xiao Z., Shen J., Zhang L., Li M., Hu W., Cho C.: “Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma: Recent progress and future prospects”. Oncol. Lett., 2018, 15, 3395.

[17] Chen S., Zhu J., Wang F., Guan Z., Ge Y., Yang X., et al.: “LncRNAs and their role in cancer stem cells”. Oncotarget, 2017, 8, 110685.

[18] Campos-Parra A.D., Lopez-Urrutia E., Orozco Moreno L.T., LopezCamarillo C., Meza-Menchaca T., Figueroa Gonzalez G., et al.: “Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer”. Int. J. Mol. Sci., 2018, 19, pii: E2711.

[19] Hou P., Zhao Y., Li Z., Yao R., Ma M., Gao Y., et al.: “LincRNAROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis”. Cell. Death. Dis., 2014, 5, e1287.

[20] Hou L., Tu J., Cheng F., Yang H., Yu F., Wang M., et al.: “Long noncoding RNA ROR promotes breast cancer by regulating the TGFbeta pathway”. Cancer. Cell. Int., 2018, 18, 142.

[21] Peng W.X., Huang J.G., Yang L., Gong A.H., Mo Y.Y.: “Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer”. Mol. Cancer, 2017, 16, 161.

[22] Bai F., Yin Y., Chen T., Chen J., Ge M., Lu Y., et al.: “Development of liposomal pemetrexed for enhanced therapy against multidrug resistance mediated by ABCC5 in breast cancer”. Int. J. Nanomedicine, 2018, 13, 1327.

[23] Chen Y.M., Liu Y., Wei H.Y., Lv K.Z., Fu P.F.: “Large intergenic non-coding RNA-ROR reverses gemcitabine-induced autophagy and apoptosis in breast cancer cells”. Oncotarget, 2016, 7, 59604.

[24] Zhang H.Y., Liang F., Zhang J.W., Wang F., Wang L., Kang X.G.: “Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205”. Cancer Chemother. Pharmacol., 2017, 79, 327.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time